Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: A systematic review

PharmacoEconomics

Volumn 31, Issue 1, 2013, Pages 63-75

  Buti, María ^a   Oyagüez, Itziar ^b   Lozano, Virginia ^b   Casado, Miguel A ^b  

^a HOSPITAL GENERAL DE CATALUNYA   (Spain)

^b Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; TENOFOVIR DIFUMARATE; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; CONFLICT OF INTEREST; COST EFFECTIVENESS ANALYSIS; CRITERION RELATED VALIDITY; DRUG INDUSTRY; ELECTRONIC MEDICAL RECORD; HEALTH CARE INDUSTRY; HEPATITIS B; HUMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ADENINE; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; GUANINE; HEALTH CARE COSTS; HEPATITIS B, CHRONIC; HUMANS; MODELS, ECONOMIC; ORGANOPHOSPHONATES; REPRODUCIBILITY OF RESULTS;

EID: 84876211742     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-012-0009-2     Document Type: Review

References (69)

1. Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med. 2004;350:1118-29.
2. Lok ASF, McMahon BJ. Chronic hepatitis B: AASLD practice guidelines. Hepatology. 2007;45:507-39.
3. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-75.
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-42.
5. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
6. Mommeja-Marin H, Mondou E, Blum MR, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37:1309-19.
7. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;3:263-83.
8. Brown R, Cock E, Colin X, et al. Hepatitis B management costs in France, Italy, Spain and the United Kingdom. J Clin Gastroenterol. 2004;38:S169-74.
9. Idris BI, Brosa M, Richardus JH, et al. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. Eur J Gastroenterol Hepatol. 2008;20:320-6.
10. Simoens S. How to assess the value of medicines? Front Pharmacol. 2010;1:115.
11. García-Altés A, Navas E, Soriano MA. Economic evaluation of public health interventions [in Spanish]. Gac Sanit. 2011;25(Suppl. 1):25-31.
12. Ijzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl Health Econ Health Policy. 2011;9(5):331-47.
13. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. York: University of York; 2008. http://www.york.ac.uk/inst/crd/pdf/Systematic-Reviews.pdf. Accessed 29 Sept 2011.
14. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.
15. Arnold E, Yuan Y, Iloeje U, et al. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy. 2008;6(4):231-46.
16. Buti M, Brosa M, Casado MA, et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. 2009;51(4):640-6.
17. Colombo GL, Gaeta GB, Vigano M, et al. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clin Outcomes Res. 2011;3(1):37-46.
18. Costa AM, L 'italien G, Nita ME, et al. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil. Braz J Infect Dis. 2008;12(5):368-73.
19. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010;13(8):922-33.
20. Dakin H, Sherman M, Fung S, et al. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. Pharmacoeconomics. 2011;29(12):1075-91.
21. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006;101(9):2076-89.
22. Lui YY, Tsoi KK, Wong VW, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther. 2010;15(2):145-55.
23. Orlewska E, Zammit D, Yuan Y, et al. The cost-effectiveness analysis of entecavir in the treatment of chronic hepatitis B (CHB) patients in Poland. Exp Clin Hepatol. 2008;4(3-4):20-8.
24. Schwierz C, Thiry N, Van de Sande S, et al. Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium: part 2 [KCE reports 157B]. Brussels: Belgian Health Care Knowledge Centre (KCE); 2011. http://test.kce.fgov.be/sites/default/files/page-documents/kce-157b- h%C3%A9patite%20b-chronique-tome%202.pdf. Accessed 10 Oct 2011.
25. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2008;26(11):937-49.
26. Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25(11):963-77.
27. Veenstra DL, Spackman DE, Di Bisceglie A, et al. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2008;27(12):1240-52.
28. Wu B, Li T, Chen H, et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010;13(5):592-600.
29. Yuan Y, Iloeje U, Li H, et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health. 2008;11(Suppl 1):S11-22.
30. Yuan Y, Iloeje UH, Hay J, et al. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm. 2008;14(1):21-33.
31. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11(3):527-38.
32. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-10.
33. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-20.
34. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
35. Iloeje UH, Yang SI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-86.
36. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010;13(8):934-45.
37. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-55.
38. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123:1831-8.
39. Thomas HC, Manns PM, Gish RG, et al. Decline in serum HBV DNA and ALT normalization is associated with histological response among nucleoside naïve patients in entecavir phase III trials. J Hepatol. 2005;42(Suppl 2):192-3.
40. Fattovich G, Giustina G, Schalm S, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology. 1995;21:77-82.
41. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
42. Davis GL, Hoofnagle JH. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology. 1984;86:230-5.
43. Chan HLY, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53:1494-8.
44. Heathcote EJ, Gane EJ, de Man RA, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis [abstract no. 158]. In: 59th Annual Meeting of the American Association for the Study of Liver Diseases. 31 Oct-4 Nov 2008. San Francisco.
45. Marcellin P, Buti M, Krastev Z, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102) [abstract no. 146]. In: 59th Annual Meeting of the American Association for the Study of Liver Diseases. 31 Oct-4 Nov 2008. San Francisco.
46. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437-44.
47. Yao G, Chen C, Lu W, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007;1(3):365-7.
48. Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol. 2009;50(2):289-95.
49. Horsmans Y, Thiry N, le Polain M, et al. Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: literature review and results of a national study [KCE reports 127C]. Brussels: Belgian Health Care Knowledge Centre (KCE); 2010. https://kce.fgov.be/sites/default/files/page- documents/d20101027324.pdf. Accessed 10 Oct 2011.
50. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-86.
51. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-10.
52. Gish R, Chang T, De Man RA, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). In: 56th American Association for the Study of Liver Diseases Annual Meeting; 11-15 Nov 2005; San Francisco.
53. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493-6.
54. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522-7.
55. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886-95.
56. Lin YT, Liu YH. Epidemiological study of hepatitis B in 1990-2003 in Wuxi City, Jiangsu Province [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25(12):1083.
57. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486-500.
58. Liaw YF, Nancy L, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-83.
59. Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother. 2007;60:201-5.
60. Sun X, Qin WX, Li YP, et al. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. J Gastroenterol Hepatol. 2007;22(9):1369-77.
61. Angus PW. Hepatitis B: weighing the costs of treatment. J Gastroenterol Hepatol. 2002;17(7):737-8.
62. Holbrook ML. Cost-effective pharmacologic therapies to treat chronic hepatitis B: how far have we really come? J Manag Care Pharm. 2008;14(1):65-9.
63. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2010;19(3):350-64.
64. Carande-Kulis VG, Maciosek MV, Briss PA, et al. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services. Am J Prev Med. 2000;18(1 Suppl):75-91.
65. Jung KT, Shin DW, Lee KJ, et al. Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review. J Clin Neurol. 2010;6(3):117-26.
66. Mauskopf JA, Baker CL, Monz BU, et al. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ. 2010;13(3):403-17.
67. Han SH. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs. 2006;66(14):1831-51.
68. Briggs A. Transportability of comparative effectiveness and cost-effectiveness between countries. Value Health. 2010;13(Suppl. 1):S22-5.
69. Vemer P, Rutten-van Mölken MP. Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. Eur J Health Econ. 2011;12(5):397-404.